Favrille drug fails secondary goal
14th Nov 2006, 06:12 GMT
Favrille has said that its drug FavId failed to reach statistical significance in a secondary endpoint but still produced favorable results in a phase III trial in patients with non-Hodgkin's lymphoma.
Favrille drug fails secondary goal related news:
- Favrille Drug Misses Secondary Target — Pharmaceuticals News from StratCenter.com
- Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial Of FavId Following Rituxan — Health News from Medical News Today
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma — Bio-Technology News from StratCenter.com
- Favrille 3Q Loss Widens on Costs — StratWire - Business of Healthcare NewsFeed
- Favrille Reports Q3 2006 Financial Results — StratWire - Business of Healthcare NewsFeed
- 'UK FBI' fails to hit asset target — Scotsman.com News - UK
- AHA: Women Receive Less Cardiovascular Secondary Prevention — MedPage Today Cardiovascular
- Guidelines on Secondary Prevention of Ischemic Stroke — Medscape Med Students Headlines
- Ferry route fails to attract bids — BBC News | UK News | Politics | Scotland politics | World Edition
- Zydus Cadila files drug application to treat obesity — NewKerala Business India News
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol
- ZymoGenetics, Serono present positive results for atacicept